163,738 Shares in Trevi Therapeutics, Inc. $TRVI Purchased by Exome Asset Management LLC

Key Points

• Exome Asset Management LLC has acquired a new stake in Trevi Therapeutics, purchasing 163,738 shares valued at approximately $1.03 million, representing about 0.16% ownership in the company.
• Shares of Trevi Therapeutics have seen an increase of 8.4%, with current trading around $7.60 and a market cap of approximately $925.53 million.
• Analysts have issued mixed ratings on Trevi Therapeutics, with the average target price set at $21.75, reflecting a consensus recommendation of "Buy" from multiple research firms.

Exome Asset Management LLC bought a new stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 163,738 shares of the company's stock, valued at approximately $1,030,000. Exome Asset Management LLC owned 0.16% of Trevi Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James Financial Inc. purchased a new position in shares of Trevi Therapeutics in the fourth quarter valued at $49,000. Squarepoint Ops LLC purchased a new position in shares of Trevi Therapeutics in the fourth quarter valued at $58,000. Two Sigma Advisers LP purchased a new position in shares of Trevi Therapeutics in the fourth quarter valued at $66,000. ProShare Advisors LLC boosted its stake in shares of Trevi Therapeutics by 86.4% in the fourth quarter. ProShare Advisors LLC now owns 20,685 shares of the company's stock valued at $85,000 after purchasing an additional 9,589 shares during the period. Finally, Diversified Trust Co purchased a new position in shares of Trevi Therapeutics in the first quarter valued at $94,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics Stock Performance

Shares of Trevi Therapeutics stock traded down $1.50 during trading hours on Friday, reaching $8.25. The company's stock had a trading volume of 3,619,982 shares, compared to its average volume of 2,887,783. The company's 50 day simple moving average is $7.36 and its 200 day simple moving average is $6.55. Trevi Therapeutics, Inc. has a one year low of $2.36 and a one year high of $9.92. The stock has a market cap of $1.00 billion, a P/E ratio of -19.64 and a beta of 0.71.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. On average, sell-side analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

TRVI has been the subject of several analyst reports. HC Wainwright started coverage on shares of Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a "buy" rating and a $21.00 target price for the company. Oppenheimer reiterated an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Morgan Stanley started coverage on shares of Trevi Therapeutics in a research note on Thursday, August 21st. They set an "overweight" rating and a $18.00 price objective on the stock. D. Boral Capital reiterated a "buy" rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Finally, Wall Street Zen downgraded shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $21.75.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.